Tandem Diabetes Care Inc. (TNDM) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Tandem Diabetes Care Inc. (TNDM)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

36.71

0.92 (2.57%)

At close: Jan 15, 2025, 9:30 AM

undefined% (undefined)

Bid	36.29
Market Cap	2.41B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.94
PE Ratio (ttm)	-18.92
Forward PE	n/a
Analyst	Buy

Ask	36.97
Volume	15,046
Avg. Volume (20D)	1,342,995
Open	36.71
Previous Close	35.79
Day's Range	36.71 - 36.71
52-Week Range	21.85 - 53.69
Beta	undefined

About TNDM

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technolo...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Nov 14, 2013

Employees 2,400

Stock Exchange NASDAQ

Ticker Symbol TNDM

Website https://www.tandemdiabetes.com

Analyst Forecast

According to 15 analyst ratings, the average rating for TNDM stock is "Buy." The 12-month stock price forecast is $55, which is an increase of 49.82% from the latest price.

Buy 86.67%

Hold 13.33%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Tandem Diabetes Care Inc. is scheduled to release its earnings on Feb 19, 2025, during market hours.
Analysts project revenue of $251.39M, reflecting a 27.74% YoY growth and earnings per share of -0.24, making a -11.11% decrease YoY.

Why Price Moved

3 weeks ago · Source

+7.94%

Tandem Diabetes Care shares are trading higher ami... Unlock content with Pro Subscription

1 month ago · Source

+6.14%

Tandem Diabetes Care shares are trading higher after Morgan Stanley upgraded the stock from Equal-Weight to Overweight.

News

6 days ago · zacks.com

Tandem Diabetes Forges New R&D Agreement With UVA: Stock to Gain?

TNDM enters a multi-year research collaboration with the UVA Center for Diabetes Technology for the development of AID systems.

1 week ago · businesswire.com

Tandem Diabetes Care Enters Multi-Year Research Collaboration with UVA Center for Diabetes Technology for Development of Advanced Insulin Delivery Systems

SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced it has signed a multi-year collabor...

1 month ago · zacks.com

TNDM Stock to Gain From t:slim X2 With Dexcom G7 Launch in Canada

Tandem Diabetes' t:slim X2 insulin pump is now compatible with Dexcom G7 CGM in Canada.

1 month ago · zacks.com

Reasons to Retain TNDM Stock in Your Portfolio for Now

Innovations and a robust international market expansion raise investors' optimism for Tandem Diabetes.

1 month ago · businesswire.com

Tandem Diabetes Care Announces Upcoming Conference Presentations

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the ...

2 months ago · zacks.com

TNDM Q3 Earnings Beat, '24 Sales View Up, Stock Falls in Aftermarket

Tandem Diabetes' top and bottom lines outpace estimates in the third quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.

2 months ago · seekingalpha.com

Tandem Diabetes Care, Inc. (TNDM) Q3 2024 Earnings Conference Call Transcript

2 months ago · zacks.com

Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key ...

2 months ago · zacks.com

Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Tops Revenue Estimates

Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.38 per share a year ago.

2 months ago · businesswire.com

Tandem Diabetes Care Announces Upcoming Conference Participation

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will host meetings and present a comp...

2 months ago · zacks.com

Down -21.69% in 4 Weeks, Here's Why Tandem Diabetes Care (TNDM) Looks Ripe for a Turnaround

Tandem Diabetes Care (TNDM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts ...